By P Reed Maurer
Final figures are not yet available, but the ethical pharmaceutical market in Japan will most likely exceed $5.5 billion at ex-manufacturers' sales level in 1995. The Japanese market is two-thirds the size of that of the USA and on a par with all the markets in western Europe combined.
Although there is a propensity in the west to forecast a demise of the Japanese market, value in dollar terms continues to grow at 5%, with volume growth in excess of 9%. To be sure, growth rates in the 1990s have slowed from the torrid pace of previous decades, but the market now accounts for almost one fourth of the worldwide sales of pharmaceuticals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze